Abstract
Understanding the dynamics of the COVID-19 pandemic, evaluating the efficacy of past and current control measures, and estimating vaccination needs, requires knowledge of the number of infections in the population over time. This number, however, generally differs substantially from the number of confirmed cases due to a large fraction of asymptomatic infections as well as geographically and temporally variable testing effort and strategies. Here I use age-stratified death count statistics, age-dependent infection fatality risks and stochastic modeling to estimate the prevalence and growth of SARS-CoV-2 infections among adults (age ≥ 20 years) in 171 countries, from early 2020 until April 9, 2021. The accuracy of the approach is confirmed through comparison to previous nationwide general-population seroprevalence surveys in multiple countries. Estimates of infections over time, compared to reported cases, reveal that the fraction of infections that are detected vary widely over time and between countries, and hence comparisons of confirmed cases alone (between countries or time points) often yield a false picture of the pandemic’s dynamics. As of April 9, 2021, the nationwide cumulative SARS-CoV-2 prevalence (past and current infections relative to the population size) is estimated at 61% (95%-CI 42-78) for Peru, 58% (39–83) for Mexico, 57% (31–75) for Brazil, 55% (34–72) for South Africa, 29% (19-48) for the US, 26% (16–49) for the United Kingdom, 19% (12–34) for France, 19% (11–33) for Sweden, 9.6% (6.5–15) for Canada, 11% (7–19) for Germany and 0.67% (0.47–1.1) for Japan. The presented time-resolved estimates expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 171 countries. Regular updates are available at: www.loucalab.com/archive/COVID19prevalence
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a US National Science Foundation RAPID grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Improved methods; updated estimates to cover more recent dates; updated discussion.
Data Availability
All data used in this manuscript were obtained from publicly accessible sources.